Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tricaprilin (AC-SD-03) PK/Safety in Healthy Older Volunteers
NCT04268953Phase 1Completed
- Sponsor
- Cerecin
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tricaprilin in Alzheimer's disease (AD), sponsored by Cerecin. Primary endpoint: Safety and tolerability of multiple-dose administrations at 32 days. Started Feb 2020; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04268953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268953.